Reports and Briefs on Therapy Area in China

Published within

« | 1 | 2 | 3 | » »|

Type Product title / description Pub Price
Report
Report

Stakeholder Insight: COPD in Emerging Markets (Brazil, India, China, US) - Key differences in treatment despite standardized guidelines

Datamonitor's survey of 300 respiratory experts in Brazil, India, China and the US addresses increased interest in COPD in the emerging markets. The US is included as a benchmark, providing unique insight and comparisons of COPD market dynamics.

Published By Datamonitor
22 Dec 2010 $15200
Buy
Report
Report

Commercial Insight: Antidiabetics in China - Rising patient numbers and novel products drive the future market

Discussion of the Chinese diabetes market including epidemiology, market drivers, and strategic analysis of key players. Assessment of marketed and pipeline products. Commercial forecast of market size and product sales and volumes to 2019.

Published By Datamonitor
21 Feb 2011 $2800
Buy
Report
Report

Epidemiology: Hepatitis B in China - Hepatitis B will continue to remain a public health burden in China, despite a a projected decrease in prevalent cases

Overview of hepatitis B definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year prevalent forecast and key patient segments across an emerging market.

Published By Datamonitor
12 Mar 2011 $2800
Buy
Report
Report

Epidemiology: Diabetes in China - Aging population, rising overweight and obesity are driving the diabetes epidemic

Diabetes mellitus is becoming an important chronic disease in countries experiencing rapid economic growth, especially China. In 2010, Datamonitor estimates that there were nearly 95 million people with diabetes mellitus in China.

Published By Datamonitor
16 Mar 2011 $2800
Buy
Report
Report

CNS Market Access in China - Investment in mental health services offers growth opportunities for psychiatry players

This report examines the CNS market in China. It reviews the epidemiology and treatment of key conditions. It also provides analysis of the strengths, weaknesses, opportunities and threats of the market and strategies for market penetration.

Published By Datamonitor
05 Jul 2011 $2800
Buy
Report
Report

Oncology Market Access in China – Market bolstered by rising incidence and improved regulatory environment

Review of the oncology market in China including; a market overview, patient care pathways, opportunities and threats, key companies involved in the market, and strategies for market penetration.

Published By Datamonitor
18 Jul 2011 $2800
Buy
Report
Report

Autoimmune Market Access in China – New biologic therapies drive future growth

Despite ongoing competition from biosimilars, branded biologics will continue to drive the Chinese autoimmune market, with two new brands, Enbrel (etanercept; Pfizer) and Humira (adalimumab; Abbott), having been approved and launched in 2010.

Published By Datamonitor
14 Sep 2011 $2800
Buy
Report
Report

Vaccine Market Access in China – M&A paves the way for foreign companies

While the category 1 vaccine market in China remains dominated by domestic manufacturers, foreign vaccine players are increasing their uptake in the category 2 vaccine market through M&A deals with local companies.

Published By Datamonitor
07 Nov 2011 $2800
Buy
Report
Report

Product Profiles: COPD in China – Novel therapies to diversify treatment options

Unmet needs continue to drive development in the Chinese COPD market. A number of novel products could become strong competitors, but they will need to overcome the strong reputation and favorable reimbursement of currently available products.

Published By Datamonitor
14 Nov 2011 $6400
Buy
Report
Report

Epidemiology: Hepatitis C in China – Epidemic yet to reach its peak

Datamonitor provides an estimate and 10-year forecast of prevalent HCV cases in China. Prevalent cases are segmented by age and gender.

Published By Datamonitor
15 Nov 2011 $4800
Buy

« | 1 | 2 | 3 | » »|

No help is available.